Zyprexa reps told to "neutralize" diabetes link

Documents unsealed in Alaska show that Eli Lilly sales reps touting Zyprexa were told to "neutralize the diabetes/hyperglycemia issue" that arose when doctors started pointing out that the drug might lead to the disease. "The competition wins when we are distracted into talking about diabetes," the documents state. Lilly says it hasn't downplayed Zyprexa's risks and that the documents are "a tiny fraction" of those provided as part of the Alaska lawsuit over the drug. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.